AVLN insider filings
Avalyn Pharma Inc. — 21 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-19. Screen AVLN transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 7 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 18 legs across 5 filings by 5 insiders — 322,429 shares, $9,319,518 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 11.
- Largest priced transaction: sale of 173,661 shares @ $29.06 ($5,046,589) by FMR LLC, filed 2026-11-12.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| FMR LLC — 10% owner | 1 | — | 4 legs · 228,454 sh · $6,701,004 | — |
| Baranowski Lyn — Chief Executive Officer, Director | 1 | — | 5 legs · 52,500 sh · $1,461,457 | 4 |
| Carlson Douglas R — See Remarks | 1 | — | 3 legs · 14,875 sh · $414,983 | 2 |
| Rhodes Melissa — Chief Operating Officer | 1 | — | 3 legs · 13,300 sh · $371,046 | 2 |
| Lazarus Howard — Chief Medical Officer | 1 | — | 3 legs · 13,300 sh · $371,027 | 2 |
| Meyer Robert J. — Director | 2 | — | — | 1 |
Recent insider filings — Avalyn Pharma Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-19 | 4 | Lazarus Howard — Chief Medical Officer | Option exercise (M): 13,300 @ $4.62 · Sale (S): 11,023 @ $27.80 · Sale (S): 2,066 @ $28.27 · Sale (S): 211 @ $29.27 · Option exercise (M): 13,300 (derivative) @ $0 | EDGAR |
| 2026-11-19 | 4 | Carlson Douglas R — See Remarks | Option exercise (M): 14,875 @ $4.62 · Sale (S): 11,527 @ $27.78 · Sale (S): 3,093 @ $28.22 · Sale (S): 255 @ $29.23 · Option exercise (M): 14,875 (derivative) @ $0 | EDGAR |
| 2026-11-19 | 4 | Rhodes Melissa — Chief Operating Officer | Option exercise (M): 13,300 @ $4.62 · Sale (S): 10,875 @ $27.79 · Sale (S): 2,025 @ $28.21 · Sale (S): 400 @ $29.23 · Option exercise (M): 13,300 (derivative) @ $0 | EDGAR |
| 2026-11-19 | 4 | Baranowski Lyn — Chief Executive Officer, Director | Option exercise (M): 45,300 @ $4.62 · Sale (S): 39,600 @ $27.76 · Sale (S): 5,300 @ $28.15 · Sale (S): 400 @ $29.22 · Option exercise (M): 7,200 @ $4.62 · Sale (S): 6,465 @ $27.90 · +3 more | EDGAR |
| 2026-11-12 | 4 | FMR LLC — 10% owner | Sale (S): 173,661 @ $29.06 · Sale (S): 1,339 @ $29.75 · Sale (S): 5,565 @ $29.56 · Sale (S): 47,889 @ $30.28 | EDGAR |
| 2026-09-17 | 3 | Meyer Robert J. — Director | Holdings only — no transactions reported | EDGAR |
| 2026-09-17 | 4 | Meyer Robert J. — Director | Grant/award (A): 31,182 (derivative) @ $0 | EDGAR |
| 2026-05-05 | 4 | FMR LLC — 10% owner | Conversion (C): 727,585 · Conversion (C): 80,291 · Conversion (C): 872,868 · Conversion (C): 225,843 · Conversion (C): 377,948 · Conversion (C): 727,585 (derivative) · +4 more | EDGAR |
| 2026-05-05 | 4 | Novo Holdings A/S — 10% owner | Conversion (C): 3,327,734 · Purchase (P): 555,555 @ $18 · Conversion (C): 18,000,000 (derivative) @ $0 · Conversion (C): 1,986,369 (derivative) @ $0 · Conversion (C): 25,899,284 (derivative) @ $0 · Conversion (C): 5,587,603 (derivative) @ $0 · +1 more | EDGAR |
| 2026-05-04 | 4 | Golden Adam H. — General Counsel | Grant/award (A): 254,891 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Carroll Jill — Director | Conversion (C): 1,419,298 · Conversion (C): 489,486 · Purchase (P): 277,778 @ $18 · Conversion (C): 27,309,719 (derivative) · Conversion (C): 9,418,561 (derivative) | EDGAR |
| 2026-05-01 | 4 | SR ONE CAPITAL MANAGEMENT, LLC — 10% owner George Simeon — 10% owner | Conversion (C): 1,419,298 · Conversion (C): 489,486 · Purchase (P): 277,778 @ $18 · Conversion (C): 354,824 · Conversion (C): 489,486 · Purchase (P): 277,777 @ $18 · +4 more | EDGAR |
| 2026-05-01 | 4 | Congleton Jon — Director | Grant/award (A): 26,978 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Rhodes Melissa — Chief Operating Officer | Grant/award (A): 211,975 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Carlson Douglas R — Chief Financial Officer | Grant/award (A): 211,975 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Haviland Kate — Director | Grant/award (A): 26,978 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Wellington Biomedical Innovation Master Investors (Cayman) II L.P. — 10% owner | Conversion (C): 1,275,486 · Conversion (C): 20,482,289 (derivative) @ $0 · Conversion (C): 4,060,259 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Lazarus Howard — Chief Medical Officer | Grant/award (A): 211,975 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Lavelle Erin — Director | Grant/award (A): 26,978 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Baranowski Lyn — Chief Executive Officer, Director | Grant/award (A): 501,033 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Turner Heather D — Director | Grant/award (A): 26,978 (derivative) @ $0 | EDGAR |
Recent 8-K events — Avalyn Pharma Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-16 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-01 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-17 | 8-K | 7.01 — Regulation FD Disclosure | EDGAR |
| 2026-06-03 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-01 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=AVLN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs